Viatris Inc (LTS:0A5V)
$ 11.7525 0 (0%) Market Cap: 15.62 Bil Enterprise Value: 29.60 Bil PE Ratio: 0 PB Ratio: 0.79 GF Score: 69/100

Viatris Inc at Raymond James Institutional Investors Conference Transcript

Mar 08, 2022 / 08:25PM GMT
Release Date Price: $9.86 (-2.52%)
Elliot Henry Wilbur
Raymond James & Associates, Inc., Research Division - Senior Research Analyst

Good afternoon. Welcome to the Viatris presentation at Raymond James' 43rd Annual Institutional Investor Conference. Viatris is an emerging global pharmaceutical leadership name, formed via the combination of Pfizer's legacy Upjohn business and Mylan's global generics and specialty branded products business.

From the company here today, CEO, Michael Goettler; CFO; Sanjeev Narula. Michael?

Michael Goettler
Viatris Inc. - CEO & Executive Director

Yes. Thank you, Elliot, and thanks for inviting us. Just wanted for those that are not that familiar with the name, summarize a little bit. We had -- about a week ago, we had an investor event, and I just want to summarize what we announced.

We announced, number one, a deal with Biocon Biologics on combining our biosimilar business in return for up to $3.335 billion, $2 billion upfront and then some participation in 12.9% stake in the future company. That's a deal that is, number one, creating a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot